Molecular data
| Physical form | Lyophilized powder blend |
|---|---|
| Available sizes | 10mg / 2mg, 5mg / 1mg, 12.5mg / 2.5mg |
What is in the vial
GLP-3 / Cagri combines 2 named components in one vial, 10mg / 2mg / 5mg / 1mg / 12.5mg / 2.5mg. 1 of the 2 is separately catalogued; the other is named here but has no entry of its own. A blend has no single molecular formula or sequence, which is why this entry carries neither.
- GLP-3
- Cagri
How it works
-
GLP-3 RT
Triple Incretin & Glucagon Agonism
GLP-3 RT binds GLP-1, GIP and glucagon receptors. Published characterisation describes glucose-dependent insulin secretion, appetite-pathway signalling and hepatic energy expenditure in study models.
- GLP-1 receptor agonism
- GIP receptor co-agonism
- Glucagon receptor agonism
-
Cagri
Amylin & Calcitonin Receptor Agonism
Cagri is a long-acting amylin analogue. It activates amylin receptors and the calcitonin receptor, with satiety signalling, gastric emptying and post-meal glucagon as measured endpoints.
- Amylin receptor agonism
- Calcitonin receptor co-activation
- Hindbrain satiety signalling
-
Synergy
Complementary Receptor Systems
The two components act through non-overlapping receptor families: incretin and glucagon receptors for GLP-3 RT, amylin and calcitonin receptors for Cagri. Amylin analogues are studied alongside incretin agonists in combination research.
- Non-overlapping receptor families
- Incretin + amylin pathway coverage
- Studied as a combined condition
What the research shows
-
Metabolic
Multi-Receptor Metabolic Research
GLP-3 RT covers three incretin and glucagon receptors; Cagri adds the amylin system. The blend is studied as a five-receptor combined condition.
-
Combination
Amylin + Incretin Research
Amylin analogues are studied alongside GLP-1-pathway agonists because the two act through different receptors and neural pathways.
-
Endocrine
Glycemic Pathway Research
Both components are studied for glycemic endpoints: glucose-dependent insulin secretion for GLP-3 RT, post-meal glucagon and gastric emptying for Cagri.
-
Neuroscience
Satiety Circuitry
Hypothalamic GLP-1 signalling and hindbrain amylin signalling are both studied for their roles in satiety pathways.
Specification
| Components | GLP-3 RT + Cagri |
|---|---|
| Content | 10 mg GLP-3 RT + 2 mg Cagri per vial |
| GLP-3 RT | Triple GLP-1/GIP/glucagon receptor agonist peptide |
| Cagri | Long-acting amylin analogue (amylin/calcitonin receptor agonist) |
| Form | Lyophilized powder blend |
| Purity | ≥99% per component (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Water-soluble |
| COA | Included with every order |
How it's tested
Every lot of GLP-3 / Cagri released to the catalog carries a third-party certificate of analysis. 1 documented lot is on file for this compound, with reported HPLC purity from 99.87% to 99.87% (mean 99.87%), issued by Freedom Diagnostics. 1 of 1 certificates record identity as confirmed.
- Documented lots
- 1
- Reported purity
- 99.87% to 99.87%
- Mean purity
- 99.87%
- Issuing labs
- Freedom Diagnostics
- 2026-10-14 Lot VG8ZGBFreedom Diagnostics 99.87% View certificate
Frequently asked questions
What is in this blend?
Each vial contains 10 mg of GLP-3 RT and 2 mg of Cagri, lyophilized together. GLP-3 RT is a triple GLP-1/GIP/glucagon receptor agonist; Cagri is a long-acting amylin analogue.
Why combine GLP-3 RT and Cagri?
The two act on different receptor systems. GLP-3 RT targets incretin and glucagon receptors, while Cagri targets amylin and calcitonin receptors. The combination covers both pathway families in one condition.
Has this combination been characterised as a single formulation?
No. The combination has not been characterised as a single formulation. The rationale is based on mechanisms described for each component individually.
Is this blend FDA approved?
No. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human or animal consumption, diagnosis, or treatment.
How should this blend be stored?
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Cross-references
Other entries in this volume that bear on GLP-3 / Cagri, with the reason each one is listed.
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.